Background {#sec1}
==========

The Brugada syndrome (BrS) is an autosomal dominant condition with extreme clinical variability and incomplete penetrance ([@ref28]; [@ref22]; [@ref26]). Brugada syndrome is characterized by a coved-type ST-segment elevation in the right precordial leads on the electrocardiogram (ECG) and by an increased risk of sudden cardiac death (SCD) ([@ref2]). Patients with a spontaneous type 1 BrS ECG pattern are considered at higher risk for SCD, although patients can also be diagnosed by administration of a sodium channel blocking agent, such as ajmaline ([@ref2]), which reveals the type 1 pattern. Patients can benefit from catheter ablation of the arrhythmogenic substrate (AS) located in the epicardial surface of the right ventricle (RV) ([@ref28]; [@ref44]), preventing ventricular arrhythmias (VA) recurrences. The administration of ajmaline during the epicardial catheter ablation procedure helps to determine the exact location and full extent of the AS ([@ref30]). It is widely accepted that the majority of molecularly confirmed BrS cases result from a loss-of-function mutation in *SCN5A*, which encodes for a voltage-gated sodium channel subunit (Na~v~1.5). Heterozygous mutations in *SCN5A* are the most commonly diagnosed mutations associated with BrS ([@ref4]; [@ref34]; [@ref3]) and account for 15--30% of BrS cases ([@ref16]). Nevertheless, a clear molecular confirmation is not achieved in most BrS cases, perhaps due to both locus heterogeneity and genomic imbalances undetectable by NGS methods ([@ref36]).

Type 1 neurofibromatosis (NF1) is caused by heterozygous mutations in the *NF1* gene ([@ref9]), and it is characterized by pigmentary lesions (café au lait spots, Lisch nodules, freckling) and cutaneous neurofibromas ([@ref5]; [@ref27]). Patients affected by NF1 can present with multiple organ involvement and hypertension, and they have a higher risk of developing malignant tumors than others of the same age in the general population ([@ref5]; [@ref17]). The risk of developing gliomas ([@ref5]; [@ref24]) and benign tumors ([@ref24]; [@ref1]) is even higher than the risk of developing malignant ones, and in some cases, the benign tumors can become malignant ([@ref25]). At least half of patients with NF1 also present with learning disabilities ([@ref5]). Premature death in NF1 patients is frequently caused by cardiovascular disease, especially since severe complications of NF1 include vasculopathy, hypertension, and congenital heart defects ([@ref6]).

In the present study, we report for the first time a family in which the nonsense mutation \[NM_198056.2:c. 3946C \> T (p.Arg1316\*)\] in the *SCN5A* gene and the frameshift mutation \[NM_001042492.2:c.7686delG (p.Ile2563fs\*7)\] in the *NF1* gene segregate with the clinical phenotypes BrS and NF1, respectively.

Case Presentation {#sec2}
=================

Proband (III-3) {#sec3}
---------------

Written informed consent of human subjects included in this case series report was obtained for their participation in the study and for publication of this case report. For patients under 18 years old, consent was obtained instead from the parents. The procedures employed were reviewed and approved by the Local Ethics Committee of San Raffaele Hospital, Milan, Italy. The proband is a 46-year-old male of Italian/Caucasian descent who presented with a family history characterized by a strong suspicion of NF1 on the maternal side of the family ([Figure 1](#fig1){ref-type="fig"}). In particular, his mother is affected by multiple cafè au lait spots, hyperthyroidism, and stomach malignant neoplasia (at 45 years old). His maternal grandmother had been affected by multiple cafè au lait spots and malignant gut neoplasm (age of onset unknown). A malignant gut neoplasm has been diagnosed recently also in the proband's sister (50 years old and without other clinical signs of NF1). No consanguinity in the family was reported.

![Family pedigree. Proband identified with arrow. Triangle: Molecularly confirmed *NF1* mutation; triangle with slash: genetic test for *NF1* mutation performed but negative; star: molecularly confirmed *SCN5A* mutation; star with slash: genetic test for *SCN5A* mutation performed but negative; y.o.: years old at diagnosis.](fgene-10-00050-g001){#fig1}

The proband came to our attention for NF1 genetic counseling. This diagnosis was clinically confirmed based on international criteria ([@ref8]). Indeed, our proband was affected by multiple cafè au lait spots, bilateral Lisch nodules, multiple benign skin neoplasms, bilateral axillary freckling, bilateral groin freckling, and a palpable lower left leg subcutaneous mass. We advised the patient of the need for surgical removal of this mass. After a couple of months, the proband underwent surgical removal of four left lower limb masses, all histologically confirmed as "myxoid neurofibroma." The preoperative ECG for this procedure revealed a type 2 BrS pattern. The patient then returned to us, and we recommended an electrophysiological evaluation. Therefore, the patient underwent an electrophysiological study (EPS), in which the patient tested negative for the inducibility of ventricular arrhythmias. However, the patient tested positive for BrS during a Flecainide test. One year after the first EPS, the proband repeated this procedure and was found to be inducible, and an ICD was subsequently implanted. The patient then underwent successful epicardial ablation of the AS. The potential duration map, which shows the location and extent of the AS after ajmaline administration immediately before epicardial catheter ablation, can be seen in [Figure 2](#fig2){ref-type="fig"}.

![Electrocardiograms and potential duration maps after ajmaline administration and immediately before epicardial catheter ablation. Patients: Proband, IV-9, and III-1.](fgene-10-00050-g002){#fig2}

The patient underwent genetic testing for both BrS and NF1. Next-generation sequencing was used to analyze genomic DNA extracted from saliva. Results revealed a heterozygous nonsense mutation \[c.3946C \> T (p.Arg1316\*)\] in the *SCN5A* gene (LOVD genomic variant \#0000406043, <https://databases.lovd.nl/shared/variants/0000406043>) of unknown parental origin. Sanger sequencing was used to analyze genomic DNA extracted from peripheral blood. Results revealed a heterozygous frameshift mutation \[c.7686delG (p.Ile2563fs\*7)\] in the *NF1* gene (LOVD genomic variant \#0000406041, <https://databases.lovd.nl/shared/variants/0000406041>) of unknown parental origin ([Figure 3](#fig3){ref-type="fig"}).

![Identification of the c. 3946C \> T (p.Arg1316\*) nonsense mutation in the SCN5A gene and the c.7686delG (p.Ile2563fs\*7) frameshift mutation in the NF1 gene. **(A,B)** NGS paired-end reads loaded in the IGV genome browser. The arrow indicates the position of the single nucleotide variation in SCN5A gene **(A)** and of the deletion in NF1 gene **(B)** in patients (mut) compared to a wt control sample. SCN5A gene is in the reverse orientation on the chromosome. **(C,D)** Sanger sequencing electropherograms confirm the presence of the variants in SCN5A **(C)** and NF1 **(D)** in patients and their absence in the wt control. In the electropherogram of NF1 gene analysis, reverse strand is reported.](fgene-10-00050-g003){#fig3}

Older Son (IV-9) {#sec4}
----------------

This 23-year-old male patient is the older son of the proband. He was clinically suspected for NF1, presenting with a family history of NF1 (affected father with molecular confirmation), multiple brain hamartoma (likely UBOs), multiple cafè au lait spots, and axillary and groin freckling. This clinical diagnosis was genetically confirmed with the finding of the same mutation in the *NF1* gene found in his father. This patient was inducible during an EPS and diagnosed with BrS after a positive ajmaline test. An ICD was implanted the same day. The patient subsequently underwent successful epicardial catheter ablation of the AS. The potential duration map can be seen in [Figure 2](#fig2){ref-type="fig"}. This patient was found to carry the same *SCN5A* mutation found in the proband from genomic DNA extracted from saliva.

Youngest Son (IV-10) {#sec5}
--------------------

This 16-year-old male patient is the youngest son of the proband. He presented clinically with delayed speech (after the third year of life), delayed walking (after the fourth year of life), autism spectrum disorder, and one cafè au lait spot. He was tested using genomic DNA extracted from peripheral blood for the *NF1* mutation found in his father. However, he tested negative for this mutation. Taking into consideration mood disturbances, the risk of self-aggressive behavior, and sleep disturbances, the patient was recommended to take valproic acid (750 + 500 mg/day) and risperidone (1.5 mg 2x/day +1.25 mg/day). Due to this therapy, in addition to the family history, the patient performed a 12-lead ECG, which revealed a suspicious pattern suggestive of BrS. An ajmaline test confirmed the diagnosis of BrS. Ajmaline infusion resulted immediately in a type 1 pattern and required isoproterenol infusion to reverse a ventricular arrhythmia that had resulted in a compromise of the hemodynamics. An ICD was implanted the same day. In spite of the BrS diagnosis, the patient has not yet performed an ablation procedure. This patient underwent genetic testing for BrS from genomic DNA extracted from saliva and has been found to carry the same *SCN5A* mutation present in the proband.

Eldest Brother (III-1) {#sec6}
----------------------

This 42-year-old male patient is the eldest brother of the proband. He came to our attention with a suspicion of BrS based on both family history and recurrent syncope episodes. An ajmaline test confirmed the diagnosis of BrS, and an EPS was positive for induction of VA. The patient subsequently underwent an ICD implant. The skin examination revealed multiple cafè au lait spots, axillary freckling, and a few cutaneous nodules without histological examination to date. It has been clarified that these clinical elements (together with family history) are sufficient for the clinical diagnosis of NF1, according to international criteria ([@ref8]). An ophthalmological evaluation was recommended but has not yet been performed. The patient underwent successful epicardial catheter ablation of the AS. The potential duration map can be seen in [Figure 2](#fig2){ref-type="fig"}. This patient was found to have both the *NF1* and *SCN5A* mutations found in the proband from genomic DNA extracted from saliva.

Nephew (IV-1) {#sec7}
-------------

This 18-year-old male patient is the nephew of the proband and son of patient \#III-1. At his clinical examination, multiple cafè au lait spots were detected. Taking into consideration the previous diagnosis of NF1 in this patient's first- and second-degree relatives (father and paternal uncle), NF1 was diagnosed in this patient as well, due to the clinically significant number of cafè au lait spots that totaled more than five and all with a diameter larger than 1.5 cm, according to the international criteria ([@ref42]). It is noteworthy that this patient is also affected by learning disabilities, which is particularly more prevalent in NF1 patients compared with the general population ([@ref39]).

Based on family history, this patient underwent an EPS and ajmaline test, which were both positive for VA inducibility and for the type 1 pattern. For these reasons, he received an ICD. The patient subsequently underwent successful epicardial catheter ablation of the AS. The potential duration map can be seen in [Figure 4](#fig4){ref-type="fig"}. This patient was found to have both the *NF1* and *SCN5A* mutations found in other family members from genomic DNA extracted from saliva.

![Electrocardiograms and potential duration maps after ajmaline administration and immediately before epicardial catheter ablation. Patients IV-1 and IV-2.](fgene-10-00050-g004){#fig4}

Nephew (IV-2) {#sec8}
-------------

This 18-year-old male patient is the twin brother of patient \#IV-1 and thus also the nephew of the proband and son of patient \#III-1. At his clinical examination, he showed multiple cafè au lait spots and axillary and groin freckling. Taking into consideration the previous diagnosis of NF1 in this patient's first- and second-degree relatives, NF1 was diagnosed in this patient as well. Because of the family history, this patient also underwent an EPS and ajmaline test, which were positive for VA inducibility and the type 1 pattern. An ICD was then implanted. The patient subsequently underwent successful epicardial catheter ablation of the AS. The potential duration map can be seen in [Figure 4](#fig4){ref-type="fig"}. An echocardiogram demonstrated the presence of a Chiari network ([@ref19]) in the absence of other congenital heart defects. This patient was found to have both the *NF1* and *SCN5A* mutations found in other family members from genomic DNA extracted from saliva.

Niece (IV-3) {#sec9}
------------

This 8-year-old female was diagnosed with NF1 due to the presence of multiple cafè au lait spots and Lisch nodules, as well as the family history. Due to her age, she has never been tested for BrS to date, but the 12-lead ECG demonstrated a spontaneous normal pattern. This patient is asymptomatic to date, and she was found to be positive for the familiar *NF1* mutation but negative for the familiar *SCN5A* mutation as analyzed from genomic DNA extracted from saliva.

Nephew (IV-11) {#sec10}
--------------

This 31-year-old male patient is another nephew of the proband. While his father (the proband's brother, III-5) is clinically affected by NF1 and BrS, patient IV-11 did not show any signs of NF1 when clinically examined, and he tested negative for BrS in an ajmaline challenge. This patient was found to be negative for both the *NF1* and *SCN5A* mutations found in other family members from genomic DNA extracted from saliva.

Discussion {#sec11}
==========

In this case series, we report for the first time a family in which the inherited nonsense mutation \[c. 3946C \> T (p.Arg1316\*)\] in the *SCN5A* gene segregates in association with BrS. Moreover, we also report, for the first time, the familial segregation of the novel frameshift mutation \[c.7686delG (p.Ile2563fsX40)\] in the *NF1* gene and the association of this mutation with NF1. Furthermore, to the best of our knowledge, it is the first time that any family has been reported to have both BrS and NF1. Neurofibromin plays an essential role in cardiac development. Patients with *NF1* mutations exhibit several vascular abnormalities, such as aneurysms or stenosis of the aortic, renal, and mesenteric arteries ([@ref29]). Tedesco and colleagues reported a higher incidence of heart abnormalities diagnosed by ultrasound in unrelated NF1 patients in sinus rhythm compared to controls ([@ref38]). Recently, Incecik and colleagues described a higher incidence of cardiac abnormalities in NF1 pediatric patients, with potentially poor prognoses ([@ref13]).

NF1 patients present with extreme clinical variability, including even between members of the same family. The majority of NF1 patients with vascular damage are asymptomatic, which can make diagnosis a challenge ([@ref31]). As a consequence, NF1 vasculopathy is often identified only after autopsy ([@ref11]). In cases in which NF1 leads to sudden death, the fatalities usually occur in adulthood and are usually attributed to a central nervous system tumor ([@ref18]). However, there are also reports of sudden cardiac death in young children with NF1. Kanter and colleagues described two cases of unrelated children clinically affected by NF1 and by a coronary artery occlusion, causing ventricular fibrillation and sudden death ([@ref15]). One clinical study investigating the relationship between NF1 and arrhythmias reported fewer cases of bradycardia in the NF1 patient population, suggesting the involvement of the vagus nerve ([@ref23]).

Neurofibromin plays a pivotal role in molecular and cellular pathways, particularly with an inhibitory action on Ras proteins ([@ref40]) that are potent factors in triggering cell growth and signaling ([@ref32]). Neurofibromin exists in at least four alternative primary structures. The expression of isoforms 3 and 4 has been discovered in cardiac muscle in rodents ([@ref10]). In animal models, neurofibromin is critical for heart development and prevents vascular diseases through Ras downregulation that regulates the development of endocardial cushions, ventricular growth, and fibrosis ([@ref21]; [@ref43]). The abolishment of myocardial neurofibromin expression in a knockout mouse model suggested that neurofibromin loss activates the Ras pathway, resulting in progressive cardiac hypertrophy, fibrosis, and cardiac myocyte enlargement ([@ref43]).

It has been widely demonstrated that the protein Na~v~1.5 encoded by the *SCN5A* gene is an essential controller of cardiac excitability, and recent studies underlined that loss of function mutations in *SCN5A* is associated with increased cardiac dimensions and reduced contractility ([@ref41]). Another study by Tedesco and colleagues highlighted that also NF1 patients even without arterial hypertension can show alterations in Doppler tissue imaging ([@ref37]). Understanding the clinical significance of individual *SCN5A* mutations is challenging, given the extreme clinical variability seen in patients with *SCN5A* mutations ([@ref20]; [@ref35]), the variability in the types of mutations and locations within the gene, the number of mutations, genetic heterogeneity, and the fact that some of these variants are found in the general population ([@ref14]). Regardless, nonsense heterozygous mutations in the *SCN5A* gene are generally accepted as causative of BrS ([@ref33]; [@ref7]).

In the present report, two spontaneous abortions occurred in a row, both in the first trimester. Recent literature suggests a genetic study on abortive product after the second consecutive pregnancy loss in the presence of other certain factors that occur at a higher prevalence than 1/100 women ([@ref12]). In such cases, testing for balanced translocation of the chromosomes may be considered ([@ref12]). However, in the present report, the cause of the abortions is unknown.

These data may highlight a close relationship between neurofibromatosis and BrS, because all the members genetically affected were also inducible for VAs during the EPS, which suggests a subset of patients with an aggressive BrS phenotype. Therefore, this may suggest that when neurofibromatosis and BrS are suspected, an extremely careful evaluation of these patients should be performed, as the phenotype manifestation of the combination of these diseases could be life-threatening. Further studies are warranted to investigate these findings in a larger subset of patients.

Taken together these data show how genetic counseling can be useful for a family. The molecular confirmation in asymptomatic members can prompt a clinical examination and preventive interventions. Additionally, affected individuals can be advised about the possibility of avoiding recurrence risk with medically assisted reproduction.

Concluding Remarks {#sec12}
==================

This study is the first family in which the nonsense mutation \[NM_198056.2:c. 3946C \> T (p.Arg1316\*)\] in the *SCN5A* gene and the frameshift mutation \[NM_001042492.2:c.7686delG (p.Ile2563fs\*7)\] in the *NF1* gene segregate with the clinical phenotypes BrS and NF1, respectively. NF1 patients should be routinely checked for cardiac and vascular abnormalities. The co-expression of NF1 and BrS may result in a subset of patients at higher risk of SCD who require the appropriate electrophysiological evaluation. The importance of genetic testing should be emphasized to identify family members who require clinical examinations and preventive interventions, as well as to advise about the possibility of avoiding recurrence risk with medically assisted reproduction.
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